Teachers Retirement System of The State of Kentucky Boosts Position in Amgen Inc. (NASDAQ:AMGN)

Teachers Retirement System of The State of Kentucky lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,617 shares of the medical research company's stock after acquiring an additional 1,839 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Amgen were worth $39,136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in AMGN. Capital World Investors grew its stake in shares of Amgen by 1,292.0% in the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after acquiring an additional 6,029,058 shares during the period. Norges Bank purchased a new position in shares of Amgen during the 4th quarter worth $1,541,991,000. GAMMA Investing LLC boosted its stake in shares of Amgen by 43,573.5% during the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company's stock worth $1,140,768,000 after acquiring an additional 3,653,205 shares during the last quarter. Capital International Investors boosted its stake in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after acquiring an additional 3,495,503 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Amgen by 52.7% during the 4th quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company's stock worth $858,020,000 after acquiring an additional 1,135,884 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

AMGN has been the topic of several analyst reports. Royal Bank Of Canada dropped their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price target on the stock. Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. UBS Group upped their price target on shares of Amgen from $315.00 to $326.00 and gave the stock a "neutral" rating in a research report on Monday. Finally, Piper Sandler reiterated an "overweight" rating and issued a $328.00 price target on shares of Amgen in a research report on Friday, June 27th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $308.77.

Amgen Price Performance

AMGN stock traded up $8.97 during trading on Tuesday, hitting $304.84. 1,535,723 shares of the company's stock traded hands, compared to its average volume of 2,967,286. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The business has a fifty day simple moving average of $285.90 and a 200 day simple moving average of $289.56. The stock has a market capitalization of $163.91 billion, a price-to-earnings ratio of 27.82, a P/E/G ratio of 2.66 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same quarter last year, the business earned $3.96 earnings per share. Amgen's quarterly revenue was up 9.4% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.